Vical Inc (VICL) 1.01 $VICL
Vical to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 09, 7:30PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will participate in a fireside chat discussion at the Leerink Global Healthcare Conference in New York. The discussion is scheduled for Wednesday, February 11 at 2:15 p.m. Eastern Time. A webcast of the company's discussion will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.01 (-0.01)
Insider Trading Alert - VICL, AGX And GUID Traded By Insiders
at The Street - Fri Jan 23, 9:15AM CST
Stocks with insider trader activity include VICL, AGX and GUID
VICL: 1.01 (-0.01), GUID: 6.28 (+0.18), AGX: 32.14 (-0.08)
Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 9:50AM CST
Vical announced that it has entered into an agreement with a Japanese biopharmaceutical company, AnGes MG.
VICL: 1.01 (-0.01), TKMR: 21.45 (-0.22), AMAG: 41.49 (+0.23), GSK: 47.94 (+1.99)
Insider Trading Alert - VICL, TIPT And HSP Traded By Insiders
at The Street - Thu Jan 15, 9:45AM CST
Stocks with insider trader activity include VICL, TIPT and HSP
VICL: 1.01 (-0.01), TIPT: 7.49 (+0.01), HSP: 87.35 (unch)
Vical and AnGes Announce Collaboration to Develop Therapy for Ebola Virus Disease
GlobeNewswire - Wed Jan 14, 5:27AM CST
Vical Incorporated (Nasdaq:VICL) and AnGes MG (Tokyo:4563) announced today that they have entered into collaboration to develop and commercialize an equine polyclonal antibody therapy for patients afflicted with Ebola virus disease. No medicines or vaccines are currently approved for the treatment of Ebola.
VICL: 1.01 (-0.01)
Vical Incorporated (VICL) Jumps: Stock Adds 9.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:51AM CST
Vical Incorporated (VICL) was a big mover last session, as its shares rose almost 10% on the day.
VICL: 1.01 (-0.01), AMAG: 41.49 (+0.23)
Traders Get Bullish on Shares of Vical, Shares Up 6.1% (VICL)
Comtex SmarTrend(R) - Fri Jan 09, 11:36AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 6.1% to $1.11 on 2.0x average daily volume. Thus far today, Vical has traded 940,000 shares, vs. average volume of 459,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's -0.8%) and outperformed the S&P 500 (6.1% to the S&P's -0.7%) during today's trading.
VICL: 1.01 (-0.01)
New Patents for Genital Herpes Vaccines Awarded to Vical (VICL); CBCD Reviews the Medical Evidence
PRWeb - Tue Jan 06, 11:05PM CST
"Infected with the herpes virus (HSV-1 or HSV-2)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
VICL: 1.01 (-0.01)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Hot Stock: Vical, Shares Drop 6.9% (VICL)
Comtex SmarTrend(R) - Tue Dec 16, 10:09AM CST
Vical (NASDAQ:VICL) is one of today's worst performing penny stocks, down 6.9% to $0.93 on 1.5x average daily volume. Vical has traded 507,000 shares thus far today, vs. average volume of 331,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.5%) and underperformed the S&P 500 (-6.9% to the S&P's 0.5%) during today's trading.
VICL: 1.01 (-0.01)
Is Novavax Really Worth 25 Times As Much As Vical?
Intrepid Investor - at Seeking Alpha - Mon Dec 15, 11:08AM CST
VICL: 1.01 (-0.01), NVAX: 8.80 (+0.40)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.01 (-0.01), NNVC: 2.97 (-0.05)
Agenus: Herpes Competition And Cancer Checkpoint Prospects
William Meyers - at Seeking Alpha - Thu Dec 11, 11:06AM CST
AGEN: 5.03 (-0.01), VICL: 1.01 (-0.01), MRK: 58.81 (-0.07), GNCA: 8.93 (-0.07)
Vical Completes Enrollment in Its Therapeutic HSV-2 Vaccine Clinical Trial
GlobeNewswire - Thu Dec 11, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), the predominant cause of recurrent genital herpes. The enrollment was completed on schedule as originally planned. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy of two vaccine candidates (one encoding glycoprotein D alone and the other in combination with UL46). The study is powered to show at least a 30% decrease in the viral shedding rate following 3 doses of vaccine. A total of 165 otherwise healthy HSV-2- infected patients aged 18 to 50 years were enrolled across seven U.S. trial sites. The Company expects to release efficacy data by the middle of 2015.
VICL: 1.01 (-0.01)
Vical to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, December 2, at 1:30 p.m. ET at the Piper Jaffray 26 Annual Healthcare Conference (New York, December 2- 3). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.01 (-0.01)
Vical to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Tue Nov 11, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, November 18, at 4:10 p.m. ET at the Stifel 2014 Healthcare Conference (New York, November 18 - 19). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.01 (-0.01)
Vical's (VICL) CEO Vijay Samant on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 12:22AM CDT
VICL: 1.01 (-0.01)
Vical updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:34PM CDT
VICL: 1.01 (-0.01)
Vical Reports Third Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Oct 30, 6:10AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and nine months ended September 30, 2014. The net loss for the third quarter of 2014 was $4.4 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the third quarter of 2013. Revenues for the third quarter of 2014 were $3.4 million, compared with revenues of $1.5 million for the third quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. for development and manufacturing services performed under our ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
VICL: 1.01 (-0.01)
Vical EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:40AM CDT
VICL: 1.01 (-0.01)
Vical to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 09, 7:30PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will participate in a fireside chat discussion at the Leerink Global Healthcare Conference in New York. The discussion is scheduled for Wednesday, February 11 at 2:15 p.m. Eastern Time. A webcast of the company's discussion will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.01 (-0.01)
Insider Trading Alert - VICL, AGX And GUID Traded By Insiders
at The Street - Fri Jan 23, 9:15AM CST
Stocks with insider trader activity include VICL, AGX and GUID
VICL: 1.01 (-0.01), GUID: 6.28 (+0.18), AGX: 32.14 (-0.08)
Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 9:50AM CST
Vical announced that it has entered into an agreement with a Japanese biopharmaceutical company, AnGes MG.
VICL: 1.01 (-0.01), TKMR: 21.45 (-0.22), AMAG: 41.49 (+0.23), GSK: 47.94 (+1.99)
Insider Trading Alert - VICL, TIPT And HSP Traded By Insiders
at The Street - Thu Jan 15, 9:45AM CST
Stocks with insider trader activity include VICL, TIPT and HSP
VICL: 1.01 (-0.01), TIPT: 7.49 (+0.01), HSP: 87.35 (unch)
Vical and AnGes Announce Collaboration to Develop Therapy for Ebola Virus Disease
GlobeNewswire - Wed Jan 14, 5:27AM CST
Vical Incorporated (Nasdaq:VICL) and AnGes MG (Tokyo:4563) announced today that they have entered into collaboration to develop and commercialize an equine polyclonal antibody therapy for patients afflicted with Ebola virus disease. No medicines or vaccines are currently approved for the treatment of Ebola.
VICL: 1.01 (-0.01)
Vical Incorporated (VICL) Jumps: Stock Adds 9.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:51AM CST
Vical Incorporated (VICL) was a big mover last session, as its shares rose almost 10% on the day.
VICL: 1.01 (-0.01), AMAG: 41.49 (+0.23)
Traders Get Bullish on Shares of Vical, Shares Up 6.1% (VICL)
Comtex SmarTrend(R) - Fri Jan 09, 11:36AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 6.1% to $1.11 on 2.0x average daily volume. Thus far today, Vical has traded 940,000 shares, vs. average volume of 459,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's -0.8%) and outperformed the S&P 500 (6.1% to the S&P's -0.7%) during today's trading.
VICL: 1.01 (-0.01)
New Patents for Genital Herpes Vaccines Awarded to Vical (VICL); CBCD Reviews the Medical Evidence
PRWeb - Tue Jan 06, 11:05PM CST
"Infected with the herpes virus (HSV-1 or HSV-2)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
VICL: 1.01 (-0.01)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Hot Stock: Vical, Shares Drop 6.9% (VICL)
Comtex SmarTrend(R) - Tue Dec 16, 10:09AM CST
Vical (NASDAQ:VICL) is one of today's worst performing penny stocks, down 6.9% to $0.93 on 1.5x average daily volume. Vical has traded 507,000 shares thus far today, vs. average volume of 331,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.5%) and underperformed the S&P 500 (-6.9% to the S&P's 0.5%) during today's trading.
VICL: 1.01 (-0.01)
Is Novavax Really Worth 25 Times As Much As Vical?
Intrepid Investor - at Seeking Alpha - Mon Dec 15, 11:08AM CST
VICL: 1.01 (-0.01), NVAX: 8.80 (+0.40)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.01 (-0.01), NNVC: 2.97 (-0.05)
Agenus: Herpes Competition And Cancer Checkpoint Prospects
William Meyers - at Seeking Alpha - Thu Dec 11, 11:06AM CST
AGEN: 5.03 (-0.01), VICL: 1.01 (-0.01), MRK: 58.81 (-0.07), GNCA: 8.93 (-0.07)
Vical Completes Enrollment in Its Therapeutic HSV-2 Vaccine Clinical Trial
GlobeNewswire - Thu Dec 11, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), the predominant cause of recurrent genital herpes. The enrollment was completed on schedule as originally planned. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy of two vaccine candidates (one encoding glycoprotein D alone and the other in combination with UL46). The study is powered to show at least a 30% decrease in the viral shedding rate following 3 doses of vaccine. A total of 165 otherwise healthy HSV-2- infected patients aged 18 to 50 years were enrolled across seven U.S. trial sites. The Company expects to release efficacy data by the middle of 2015.
VICL: 1.01 (-0.01)
Vical to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, December 2, at 1:30 p.m. ET at the Piper Jaffray 26 Annual Healthcare Conference (New York, December 2- 3). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.01 (-0.01)
Vical to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Tue Nov 11, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, November 18, at 4:10 p.m. ET at the Stifel 2014 Healthcare Conference (New York, November 18 - 19). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.01 (-0.01)
Vical's (VICL) CEO Vijay Samant on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 12:22AM CDT
VICL: 1.01 (-0.01)
Vical updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:34PM CDT
VICL: 1.01 (-0.01)
Vical Reports Third Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Oct 30, 6:10AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and nine months ended September 30, 2014. The net loss for the third quarter of 2014 was $4.4 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the third quarter of 2013. Revenues for the third quarter of 2014 were $3.4 million, compared with revenues of $1.5 million for the third quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. for development and manufacturing services performed under our ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
VICL: 1.01 (-0.01)
Vical EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:40AM CDT
VICL: 1.01 (-0.01)
